Direkt zum Inhalt
Merck

SML2514

Sigma-Aldrich

Nedaplatin

Synonym(e):

Nedaplatin, Cis-Diammine (Glycolato)Platinum

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C2H8N2O3Pt
CAS-Nummer:
Molekulargewicht:
303.17
UNSPSC-Code:
12352200
NACRES:
NA.77

Form

powder

Lagertemp.

2-8°C

InChI

1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2

InChIKey

KLNFSAOEKUDMFA-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Nedaplatin is a second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. Nedplatin is less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.

Piktogramme

Skull and crossbonesHealth hazard

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1B - Skin Irrit. 2 - Skin Sens. 1B - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Takuma Kagami et al.
BMC cancer, 20(1), 1123-1123 (2020-11-22)
Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma
Hongmei Zhang et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(1), 80-86 (2020-04-12)
To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. A total of 100 ovarian cancer patients treated in our hospital from January 2015 to
Jun Fu et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(4), 1707-1713 (2020-10-26)
To investigate the efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer (SCLC). 64 patients diagnosed with SCLC in our hospital from April 2013 to June 2015 were retrospectively analyzed. Thirty-two patients in
Osamu Maeda et al.
Anticancer research, 40(5), 2497-2507 (2020-05-06)
Spectrin αII contributes to cisplatin and carboplatin resistance in ovarian serous carcinoma cells, and its expression in surgical specimens is a valid predictor of prognosis. We sought to identify effective drugs for spectrin αII-mediated cisplatin-resistant cells. We employed SKOV3 cells
Tomonori Sasahira et al.
International journal of molecular sciences, 21(10) (2020-05-28)
Because oral squamous cell carcinomas (OSCCs) have a high potential for locoregional invasion and nodal metastasis, early detection and treatment are essential. A LAP2, emerin, MAN1 (LEM) domain containing 1 (LEMD1) is associated with local progression, clinical stage, nodal metastasis

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.